Physician profile
Pasquale Petrera
NPI 1215918933
$137,000.54
in general payments reported to CMS, 2019-2025
9 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $46K · 2021: $25K · 2022: $1,295 · 2024: $1,959 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $3,432 · Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $3,432.12 |
| Food and Beverage | $309.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corentec America INC | $87,762.28 | 2019-2021 | |
| Globus Medical, INC. | $44,516.82 | 2019-2025 | Onvoy, Actify 3d |
| Stryker Corporation | $2,456.87 | 2019-2024 | Mako |
| Arthrex, INC. | $884.19 | 2019 | |
| Supreme Orthopedic Systems, LLC | $694.86 | 2019 | |
| Smith+Nephew, INC. | $267.63 | 2019-2024 | Journey II |
| Molnlycke Health Care US, LLC | $219.70 | 2022 | |
| Heron Therapeutics, INC. | $179.29 | 2025 | Zynrelef |
| Nextstep Arthropedix, LLC | $18.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pasquale Petrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.